Attached files
| file | filename |
|---|---|
| EX-99.1 - VBI Vaccines Inc/BC | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 5, 2017
VBI VACCINES INC.
(Exact name of registrant as specified in its charter)
| British Columbia, Canada | 000-37769 |
N/A | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
222 Third Street, Suite 2241 Cambridge, Massachusetts |
02142 | |
| (Address of principal executive offices) | (Zip Code) |
(617) 830-3031
(Registrant’s telephone number, including area code)
| N/A |
| (Former Name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On April 5, 2017, VBI Vaccines Inc. (the “Company”) issued a press release announcing that David E. Anderson, Ph.D., the Company’s Chief Scientific Officer, and Francisco Diaz-Mitoma, M.D., Ph.D, the Company’s Chief Medical Officer, will present updates on the Company’s eVLP Platform and Sci-B-Vac™ vaccine, respectively, at the World Vaccine Congress in Washington, D.C. on Tuesday, April 11, 2017. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference in this Item 7.01.
The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed “filed” with the U.S. Securities and Exchange Commission (the “SEC”) nor incorporated by reference into any filing made under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1* | Press Release dated April 5, 2017. |
* Furnished herewith
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VBI Vaccines Inc. | |||
| Date: April 5, 2017 | By: | /s/ Jeff Baxter | |
| Jeff Baxter | |||
| President and Chief Executive Officer | |||
| 3 |
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1* | Press Release dated April 5, 2017. |
* Furnished herewith
| 4 |